UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000008611 |
|---|---|
| Receipt number | R000010124 |
| Scientific Title | A single-center open-label parallel-group study on the efficacy and the safety of survivin-2B peptide vaccine therapy for patients with advanced or recurrent digestive organ cancer, for which there is no effective treatment. |
| Date of disclosure of the study information | 2012/08/03 |
| Last modified on | 2014/04/14 15:31:53 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
A single-center open-label parallel-group study on the efficacy and the safety of survivin-2B peptide vaccine therapy for patients with advanced or recurrent digestive organ cancer, for which there is no effective treatment.
Acronym
Phase I clinical study of survivin-2B peptide vaccine therapy for patients with advanced or recurrent digestive organ cancer, for which there is no effective treatment.(SUCCESS)
Scientific Title
A single-center open-label parallel-group study on the efficacy and the safety of survivin-2B peptide vaccine therapy for patients with advanced or recurrent digestive organ cancer, for which there is no effective treatment.
Scientific Title:Acronym
Phase I clinical study of survivin-2B peptide vaccine therapy for patients with advanced or recurrent digestive organ cancer, for which there is no effective treatment.(SUCCESS)
Region
| Japan |
Condition
Condition
advanced or recurrent digestive organ cancer
Classification by specialty
| Gastrointestinal surgery | Hepato-biliary-pancreatic surgery |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
We investigate the safety of survivin-2B peptide vaccine therapy for patients with advanced or recurrent digestive organ cancer in this study. In addition, we investigate the efficacy of this vaccine therapy, immunology assessment and contracting effect on cancer.
Basic objectives2
Safety
Basic objectives -Others
Trial characteristics_1
Confirmatory
Trial characteristics_2
Explanatory
Developmental phase
Phase I
Assessment
Primary outcomes
The primary endpoint is safety: Then first we observe for adverse effects. Second, laboratory data, vital signs and weight are measured, and finally a 12-lead electrocardiogram is conducted.
Key secondary outcomes
Secondary endpoints are immunological effects and shrinkage of cancer. Immunological effects are investigated as described below. SVN-2B peptide-specific CTL frequency is evaluated by tetramer analysis. SVN-2B peptide-specific CTL response is evaluated by enzyme linked immuno-sorbent spot (ELISPOT) assay. In addition, shrinkage of cancer is evaluated by CT or MRI imaging tests before vaccination and after the fourth treatment.
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Dose comparison
Stratification
Dynamic allocation
Institution consideration
Institution is considered as a block.
Blocking
Concealment
Central registration
Intervention
No. of arms
3
Purpose of intervention
Treatment
Type of intervention
| Vaccine |
Interventions/Control_1
SVN-2B vaccine is injected under the skin at a dose of 0.3 mg/body combined with montanide ISA 51VG 1ml, once every two weeks. The treatment regimen is 4 doses.
Interventions/Control_2
SVN-2B vaccine is injected under the skin at a dose of 1.0 mg/body combined with montanide ISA 51VG 1ml, once every two weeks. The treatment regimen is 4 doses.
Interventions/Control_3
SVN-2B vaccine is injected under the skin at a dose of 3.0 mg/body combined with montanide ISA 51VG 1ml, once every two weeks. The treatment regimen is 4 doses.
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 85 | years-old | > |
Gender
Male and Female
Key inclusion criteria
(1) Patients must have been given a definitive diagnosis of gastrointestinal carcinoma.
(2) In each patient it must be confirmed that survivin protein was expressed in cancer cells.
(3) Patients must meet 1 and 2 or 1 and 3 of the following criteria.
1) Inoperable status, with distant metastasis or recurrence.
2) Patients who will be administrate their first treatment because no standard chemotherapy was either advisable or available.
3) Did not respond sufficiently to the standard chemotherapy or could not tolerate the treatment.
(4) Have measurable lesion as determined by CT or MRI during the previous observation period.
(5) Patients must be HLA-A*2402 positive.
(6) Patients who have 1.6 or less log10 (1+CTLpre): CTLpre, the number of SVN-2B peputide-specific CTL in the previous observation period (the number of SVN-2B tetramer-positive CTL over 10,000 CD8-positive T cells by the tetramer analysis).
(7) Patients must have Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1.
(8) Patients who have been confirmed as having no serious organ failure within 30 days precious to registration (neutrophil >=1,500/uL, hemoglobin level >=8.0 g/dL, platelet count >=75*103/uL, 1.5 times serum creatinine level <= normal upper limit level, a total serum bilirubin level <= normal upper limit level, AST and ALT <=2 times normal upper limit level).
(9) Patients must be 20-85 years of age at the time of agreement.
(10) Patients must receive substantial and sufficient explanation of the content of this trial in all its aspects and provide.
Key exclusion criteria
(1) Patients with an infection and who need systemic therapy such as antibiotics or antiviral medication.
(2) Patients who are positive in any test for HBV, HCV and HIV within 90 days before registration.
(3) Patients with any disorder that might preclude participation in the protocol, such as a history of severe heart failure, myocadinal infarction within 180 days before registration, arrhythmia requiring medical treatment, and those with severe obstructive lung disease.
(4) Patients with diabetes that cannot be controlled or those with hypertension.
(5) Patients with pleural effusion requiring drainage, pericardial fluid or ascites. (Patients who have had their drainage removed at least 14 days and who might be expected to participate safely, in this study, can be eligible.)
(6) Patients with brain metastatic disease and who have displayed any cranial nerve symptoms.
(7) Patients with any other life-threatening disease.
(8) Patients who cannot be evaluated adequately during the clinical course.
(9) Patients who have received SVN-2B in the past.
(10) Patients who are under treatment as described below itmes.
1) Surgery or radiotherapy.
2) Chemotherapy (including molecular targeted medicine).
3) Nitrosourea or MMC.
4) Endocrine therapy or immunotherapy (including the BRM therapy).
5) Blood transfusion,or hemopoietic factor.
6) Administration of immunosuppressive drug.
7) Other investigational new drugs or unlicensed drugs.
(11) Patients who are required to be administered steroids.
(12) Patients who have suffered from any side effect of a severity greater than Grade 2, as prescribed in CTCAE ver.4.03.
(13) Patients with a history of a serious drug allergy in the past.
(14) Pregnant women or those who are lactating.
(15) Patients who are determined as being an inappropriate study case by the trial responsibility physicians or trial allotment physicians.
Target sample size
15
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Toru Mizuguchi |
Organization
Sapporo medical university hospital
Division name
Department of surgery (I)
Zip code
Address
nishi 16 choume minami 1 jyo chuo-ku sapporo
TEL
011-611-2111
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Toshihiko Torigoe |
Organization
Sapporo medical university
Division name
Department of pathology (I)
Zip code
Address
nishi 17 choume minami 1 jyo chuo-ku sapporo
TEL
011-611-2111
Homepage URL
Sponsor or person
Institute
Sapporo medical university hospital
Institute
Department
Personal name
Funding Source
Organization
Health, Labour and Welfare Ministry
Organization
Division
Category of Funding Organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
札幌医科大学附属病院
Other administrative information
Date of disclosure of the study information
| 2012 | Year | 08 | Month | 03 | Day |
Related information
URL releasing protocol
Publication of results
Partially published
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2012 | Year | 07 | Month | 30 | Day |
Date of IRB
Anticipated trial start date
| 2012 | Year | 08 | Month | 30 | Day |
Last follow-up date
| 2013 | Year | 05 | Month | 30 | Day |
Date of closure to data entry
| 2013 | Year | 06 | Month | 06 | Day |
Date trial data considered complete
| 2014 | Year | 01 | Month | 20 | Day |
Date analysis concluded
| 2014 | Year | 01 | Month | 22 | Day |
Other
Other related information
Management information
Registered date
| 2012 | Year | 08 | Month | 03 | Day |
Last modified on
| 2014 | Year | 04 | Month | 14 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000010124
